Megostat

Megestrol acetate, the active ingredient in Megostat, is a progestin presented as an oral formulation for oral use. It is employed to stimulate appetite in patients with severe weight loss and to provide hormone therapy in certain cancers. GNH USA supplies Megostat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Megostat is a synthetic progestin that acts on metabolic and hormonal pathways to address specific disease states.

Cachexia associated with AIDS or cancer: helps improve appetite and promote weight gain. Advanced breast cancer: used as part of hormone‑based therapy to inhibit tumor progression. Endometrial cancer: employed to control disease growth through progesterone receptor modulation.

Megostat may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea or vomiting - Fluid retention or peripheral edema - Fatigue or weakness - Constipation or abdominal discomfort - Weight gain due to increased appetite

Serious or Rare Side Effects: - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Severe allergic reactions (anaphylaxis, skin rash) - Hyperglycemia or new‑onset diabetes - Cushingoid appearance (moon face, central obesity) - Adrenal insufficiency on abrupt discontinuation

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications. - Monitor blood glucose: patients with diabetes may require dose adjustments. - Assess for thrombotic risk: avoid use in individuals with recent clotting events. - Evaluate liver function: hepatic impairment can alter drug metabolism. - Review concomitant hormone therapies: potential additive effects on hormone levels. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Megostat can interact with several drug classes, necessitating careful review of a patient’s medication regimen.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may increase bleeding risk. - CYP3A4 inducers (e.g., rifampin, phenytoin): can reduce megesterol exposure.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: may exacerbate hyperglycemia. - Other glucocorticoids: additive immunosuppressive and metabolic effects. - Hormonal contraceptives: may decrease contraceptive efficacy.